Varian TrueBeam linear accelerator with BrainLAB’s Novalis provides high-energy radiation, which enables treatment with high doses of radiation while minimizing doses to surrounding, normal tissues.
“Caring for cancer patients and their families is complex and requires a comprehensive approach,” said Dr. Rajiv P. Panikkar, chair of the Geisinger Cancer Institute. “This $4.5 million investment improves patients’ experiences and outcomes. Our team can tackle complex cancers in fewer treatments and even deliver repeat radiation in certain situations.”
This cutting-edge combination is the only platform of its kind in northeastern Pennsylvania.
The Truebeam can generate high-quality, 3-D images of the tumor and the surrounding anatomy. Combined with a 6-D robotic couch system, Truebeam adjusts its targets as natural breathing moves the tumor. The TrueBeam can perform stereotactic radiosurgery, considered the most precise method of delivering a high dose of radiation into the body.
“Tumors are treated with pinpoint precision -- no surgery, no incisions and no post-surgical healing. Treatments that once took 10 to 30 minutes can now be completed in less than two minutes,” said Dr. Anand Mahadevan, radiation oncologist and chair of Radiation at Geisinger. “We’re excited to add this cancer-fighting technology to help patients here in northeastern Pennsylvania.”
For more information, call 570-808-7075.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.
For media inquiries:
Media Relations Manager